Testosterone undecanoate oral twice-daily - AbbVie/Lipocine

Drug Profile

Testosterone undecanoate oral twice-daily - AbbVie/Lipocine

Alternative Names: ABT-SLV361; LPCN-1021; TLANDO

Latest Information Update: 27 Jun 2017

Price : $50

At a glance

  • Originator Lipocine
  • Developer Abbott Laboratories; Lipocine
  • Class Anabolic steroids; Androstenols; Hormonal replacements; Small molecules; Testosterone congeners
  • Mechanism of Action Androgen receptor agonists; Testosterone replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Hypogonadism

Most Recent Events

  • 19 Jun 2017 Lipocine announces intention to resubmit NDA to the US FDA for Hypogonadism, in the third quarter of 2017
  • 19 Jun 2017 Adverse events and pharmacokinetics data from the dosing validation and dosing flexibility trial in Hypogonasidm released by Lipocine
  • 24 Apr 2017 Lipocine completes enrolment in its dosing validation trial for Hypogonasidm
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top